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Chimeric-antigen-receptor (CAR) T cells targeting CD19
show dramatic remissions in refractory or relapsed acute
lymphoblastic leukemia. Interleukin-6 (IL-6) has been
associated with severe cytokine release syndrome (CRS)
following CAR T cell treatment, leading to significant
toxicity and death. CRS could be treated with an anti-
IL6-receptor antibody, with reversal of most of the
inflammatory response within hours to days. In addition,
the significance of IL-6 in prevention and treatment of
graft-versus-host disease (GVHD) following allogeneic
bone marrow transplant (allo-BMT) has been shown in
pre-clinical and clinical settings.
Here, we used an immunocompetent murine model
of ALL to study CD19 CAR biology. In a syngeneic/
autologous model, we found no significant increase in
IL-6 in leukemia bearing mice following CD19 CAR treat-
ment. No significant alteration in efficacy was seen when
administering CD19 CAR from wild-type mice or IL6-/-
mice to wild-type or IL6-/-recipients, with all achieving
long term remissions compared to controls.
To elucidate IL-6 in this system, we used a minor-mis-
match allo-BMT mouse model (B6àC3h.sw), previously
shown to have increased IL-6 levels when T cell replete
BMT given. Using a T cell depleted allo-BMT platform,
we saw significant increase in IL-6 in leukemia bearing
mice treated with CD19 CAR T cells compared to
leukemia-bearing controls treated with mock-T cells, and
non-leukemia bearing allogeneic CAR recipients. Peak of
IL-6 levels was seen 5 days following CAR-T cell infusion,
either when given in proximity to the BMT or in later
time points. The rise in IL-6 correlated with an acute
systemic inflammatory process resembling acute GVHD,
that caused early lethality despite being a minor-mismatch
model, and at relatively low T cell doses. This acute
GVHD could not be reversed when T cells were given
early (day 0-2 post BMT), using either IL6-receptor block-
ade or IL6-/-bone marrow on day 0. However, when
leukemia and CD19 CAR administered late (day +12-+17)
following allo-BMT, wild-type marrow recipients still died
of acute GVHD while IL6-/-recipients were rescued.
Altogether, we show that IL-6 is not essential for CD19
CAR efficacy in this murine model, but can drive signifi-
cant toxicity following an allogeneic BMT with CAR.
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